Unknown PHASE2 INTERVENTIONAL 2-arm NCT03917966

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced Esophageal Squamous Cell Carcinoma

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions SHR-1210+Apatinib SHR-1210+docetaxel+nedaplatin

Updated 8 times since 2019 Last updated: Feb 16, 2022 Started: Apr 7, 2020 Primary completion: Oct 7, 2023 Completion: Oct 7, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03917966, this PHASE2 trial focuses on Locally Advanced Esophageal Squamous Cell Carcinoma and remains ongoing. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 8 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Nov 2024 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Sep 2021 — Apr 2022 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2019 — Oct 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China